Literature DB >> 19219430

Association between FDG uptake, CSF biomarkers and cognitive performance in patients with probable Alzheimer's disease.

Sönke Arlt1, Stefanie Brassen, Holger Jahn, Florian Wilke, Martin Eichenlaub, Ivayla Apostolova, Fabian Wenzel, Frank Thiele, Stewart Young, Ralph Buchert.   

Abstract

PURPOSE: Brain imaging of FDG uptake and cerebrospinal fluid (CSF) concentration of amyloid-beta 1-42 (Abeta(1-42)) or tau proteins are promising biomarkers in the diagnosis of Alzheimer's disease (AD). There is still uncertainty regarding any association between decreased FDG uptake and alterations in CSF markers.
METHODS: The relationship between FDG uptake, CSF Abeta(1-42) and total tau (T-tau), as well as the Mini-Mental State Examination (MMSE) score was investigated in 34 subjects with probable AD using step-wise linear regression. FDG uptake was scaled to the pons.
RESULTS: Scaled FDG uptake was significantly reduced in the probable AD subjects compared to 17 controls bilaterally in the precuneus/posterior cingulate area, angular gyrus/inferior parietal cortex, inferior temporal/midtemporal cortex, midfrontal cortex, and left caudate. Voxel-based single-subject analysis of the probable AD subjects at p < 0.001 (uncorrected) revealed a total volume of significant hypometabolism ranging from 0 to 452 ml (median 70 ml). The total hypometabolic volume was negatively correlated with the MMSE score, but it was not correlated with the CSF measures. VOI-based step-wise linear regression revealed that scaled FDG uptake in the precuneus/posterior cingulate was negatively correlated with CSF Abeta(1-42). Scaled FDG uptake in the caudate was positively correlated with CSF T-tau.
CONCLUSION: The extent and local severity of the reduction in FDG uptake in probable AD subjects are associated with cognitive impairment. In addition, there appears to be a relationship between local FDG uptake and CSF biomarkers which differs between different brain regions.

Entities:  

Mesh:

Substances:

Year:  2009        PMID: 19219430     DOI: 10.1007/s00259-009-1063-7

Source DB:  PubMed          Journal:  Eur J Nucl Med Mol Imaging        ISSN: 1619-7070            Impact factor:   9.236


  38 in total

1.  Discrimination between Alzheimer dementia and controls by automated analysis of multicenter FDG PET.

Authors:  K Herholz; E Salmon; D Perani; J C Baron; V Holthoff; L Frölich; P Schönknecht; K Ito; R Mielke; E Kalbe; G Zündorf; X Delbeuck; O Pelati; D Anchisi; F Fazio; N Kerrouche; B Desgranges; F Eustache; B Beuthien-Baumann; C Menzel; J Schröder; T Kato; Y Arahata; M Henze; W D Heiss
Journal:  Neuroimage       Date:  2002-09       Impact factor: 6.556

Review 2.  What's wrong with Bonferroni adjustments.

Authors:  T V Perneger
Journal:  BMJ       Date:  1998-04-18

3.  Decreased beta-amyloid1-42 and increased tau levels in cerebrospinal fluid of patients with Alzheimer disease.

Authors:  Trey Sunderland; Gary Linker; Nadeem Mirza; Karen T Putnam; David L Friedman; Lida H Kimmel; Judy Bergeson; Guy J Manetti; Matthew Zimmermann; Brian Tang; John J Bartko; Robert M Cohen
Journal:  JAMA       Date:  2003 Apr 23-30       Impact factor: 56.272

4.  FDG PET imaging in patients with pathologically verified dementia.

Authors:  J M Hoffman; K A Welsh-Bohmer; M Hanson; B Crain; C Hulette; N Earl; R E Coleman
Journal:  J Nucl Med       Date:  2000-11       Impact factor: 10.057

5.  Statistical brain mapping of 18F-FDG PET in Alzheimer's disease: validation of anatomic standardization for atrophied brains.

Authors:  K Ishii; F Willoch; S Minoshima; A Drzezga; E P Ficaro; D J Cross; D E Kuhl; M Schwaiger
Journal:  J Nucl Med       Date:  2001-04       Impact factor: 10.057

6.  Differential diagnosis of Alzheimer disease with cerebrospinal fluid levels of tau protein phosphorylated at threonine 231.

Authors:  Katharina Buerger; Raymond Zinkowski; Stefan J Teipel; Tero Tapiola; Hiroyuki Arai; Kaj Blennow; Niels Andreasen; Klaus Hofmann-Kiefer; John DeBernardis; Daniel Kerkman; Cheryl McCulloch; Russell Kohnken; Frank Padberg; Tuula Pirttilä; Marc B Schapiro; Stanley I Rapoport; Hans-Jürgen Möller; Peter Davies; Harald Hampel
Journal:  Arch Neurol       Date:  2002-08

Review 7.  Toward a molecular neuropsychiatry of neurodegenerative diseases.

Authors:  Jeffrey L Cummings
Journal:  Ann Neurol       Date:  2003-08       Impact factor: 10.422

8.  Longitudinal changes of CSF biomarkers in memory clinic patients.

Authors:  F H Bouwman; W M van der Flier; N S M Schoonenboom; E J van Elk; A Kok; F Rijmen; M A Blankenstein; P Scheltens
Journal:  Neurology       Date:  2007-09-04       Impact factor: 9.910

9.  CSF phosporylated TAU protein levels correlate with cerebral glucose metabolism assessed with PET in Alzheimer's disease.

Authors:  R Ceravolo; D Borghetti; L Kiferle; G Tognoni; A Giorgetti; D Neglia; N Sassi; D Frosini; C Rossi; L Petrozzi; G Siciliano; L Murri
Journal:  Brain Res Bull       Date:  2008-02-11       Impact factor: 4.077

10.  Preserved pontine glucose metabolism in Alzheimer disease: a reference region for functional brain image (PET) analysis.

Authors:  S Minoshima; K A Frey; N L Foster; D E Kuhl
Journal:  J Comput Assist Tomogr       Date:  1995 Jul-Aug       Impact factor: 1.826

View more
  13 in total

Review 1.  PET/CT in diagnosis of dementia.

Authors:  Valentina Berti; Alberto Pupi; Lisa Mosconi
Journal:  Ann N Y Acad Sci       Date:  2011-06       Impact factor: 5.691

2.  The mediational effects of FDG hypometabolism on the association between cerebrospinal fluid biomarkers and neurocognitive function.

Authors:  N Maritza Dowling; Sterling C Johnson; Carey E Gleason; William J Jagust
Journal:  Neuroimage       Date:  2014-10-29       Impact factor: 6.556

3.  The relationship between CSF biomarkers and cerebral metabolism in early-onset Alzheimer's disease.

Authors:  Alice Jaillard; Matthieu Vanhoutte; Aurélien Maureille; Susanna Schraen; Emilie Skrobala; Xavier Delbeuck; Adeline Rollin-Sillaire; Florence Pasquier; Stéphanie Bombois; Franck Semah
Journal:  Eur J Nucl Med Mol Imaging       Date:  2018-08-28       Impact factor: 9.236

Review 4.  Current Role for Biomarkers in Clinical Diagnosis of Alzheimer Disease and Frontotemporal Dementia.

Authors:  Nasim Sheikh-Bahaei; Seyed Ahmad Sajjadi; Aimee L Pierce
Journal:  Curr Treat Options Neurol       Date:  2017-11-14       Impact factor: 3.598

5.  [The importance of molecular imaging (PET) in the diagnostics of dementia].

Authors:  M Tscheuschler; M Gebest; F Jessen; A Drzezga
Journal:  Nervenarzt       Date:  2018-07       Impact factor: 1.214

6.  Longitudinal Partial Volume Correction in 2-[18F]-Fluoro-2-Deoxy-D-Glucose Positron Emission Tomography Studies of Alzheimer Disease.

Authors:  Charles B Malpas; Michael M Saling; Dennis Velakoulis; Patricia Desmond; Rodney J Hicks; Terence J OʼBrien
Journal:  J Comput Assist Tomogr       Date:  2015 Jul-Aug       Impact factor: 1.826

7.  Brain perfusion SPECT correlates with CSF biomarkers in Alzheimer's disease.

Authors:  Marie-Odile Habert; Leonardo Cruz de Souza; Foudil Lamari; Nelle Daragon; Serge Desarnaud; Claude Jardel; Bruno Dubois; Marie Sarazin
Journal:  Eur J Nucl Med Mol Imaging       Date:  2009-10-10       Impact factor: 9.236

8.  Early [(18)F]florbetaben and [(11)C]PiB PET images are a surrogate biomarker of neuronal injury in Alzheimer's disease.

Authors:  Solveig Tiepolt; Swen Hesse; Marianne Patt; Julia Luthardt; Matthias L Schroeter; Karl-Titus Hoffmann; David Weise; Hermann-Josef Gertz; Osama Sabri; Henryk Barthel
Journal:  Eur J Nucl Med Mol Imaging       Date:  2016-03-30       Impact factor: 9.236

Review 9.  Memory loss in Alzheimer's disease.

Authors:  Holger Jahn
Journal:  Dialogues Clin Neurosci       Date:  2013-12       Impact factor: 5.986

10.  Fluid biomarkers for diagnosing dementia: rationale and the Canadian Consensus on Diagnosis and Treatment of Dementia recommendations for Canadian physicians.

Authors:  Pedro Rosa-Neto; Ging-Yuek Hsiung; Mario Masellis
Journal:  Alzheimers Res Ther       Date:  2013-11-25       Impact factor: 6.982

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.